Methods: Cohort 2 enrolled unresectable locally advanced, locally recurrent, or metastatic ESCC patients aged 18-75 years with ECOG performance status of 0-1 who had progression on or were intolerant to first-line immunochemotherapy. The disease should be controlled without progression for at least ...
Objectives: The KEEPsAKE 1 and 2 trials have demonstrated the efficacy and safety of Risankizumab in nave and TNF-experienced patients with PsA. Here we report the real-life efficacy and safety of Risankizumab in an Italian cohort of PsA patients. Methods: In this observational retrospective...
METHODS. We conducted a retrospective, multicentre, cohort study across twenty health boards in the UK, of patients with CD treated with risankizumab between the 1st of January, 2021 and the 1st of November 2024. Our primary outcome was treatment persistence at 6 months. Our secondary ...
Median PFS was 10.85 months (95% CI, NE-NE) for cohort 1, and 11.86 months (95% CI, 6.49-16.73) for cohort 2. Grade 3-4 treatment-emergent adverse events (teAE) occurred in 50% of cohort 1 and 68% of cohort 2. No fatal adverse event was reported. The most common grade 3-4 ...
The two study cohorts are: treatment nave (Cohort 1; n=60); and failed recent (<6 months) RTX or biosimilar treatment (Cohort 2; n=40). Satralizumab monotherapy (120 mg) will be administered subcutaneously at Weeks 0, 2, 4, and Q4W thereafter for a total treatment period of 92 ...
P046 Real-world data on the treatment with Mirikizumab in a mostly biological-experienced Ulcerative colitis cohortdoi:10.1093/ecco-jcc/jjad212.0176BACKGROUND. Mirikizumab was approved for treating Ulcerative colitis (UC) in May 2023. However, real-world data, especially in biological-experienced ...
Real﹚orld data on emicizumab use and monitoring in paediatric severe haemophilia A (HA) patients are scarce. We therefore sought to evaluate safety, efficacy, and laboratory monitoring of emicizumab prophylaxis in a cohort of 40 children with severe HA, including 22 non﹊nhibitor patients and...
85% of 3-month cohort patients received at least two doses of crizanlizumab, while 66% of the 6-month cohort received at least 4 doses of crizanlizumab. The median number of gap days between doses was 1 or 2.Conclusions66% of patients who receive crizanlizumab receive at least 4...
Response was re-captured in 4/6 patients with secondary loss of response following 4-weekly dose intensification. No adverse events were observed during the follow-up period. CONCLUSION. Risankizumab was highly effective for Crohn's disease in an Emirati cohort, especially in AT-naive patients ...
Pts who completed systemic therapy >6 months before the study, if given as part of multimodal treatment for locally advanced disease, are eligible. In the tebotelimab cohort, safety data will be reviewed for dose-limiting toxicities through Cycle 2 Day 7 on the first 12 pts (2 mini cohorts...